Synlogic Reports Third Quarter 2017 Financial Results and Recent Progress

Synlogic to Present at Upcoming Investor Conferences in November

Synlogic Reports Positive Top-Line Phase 1 Data Demonstrating Safety and Tolerability and Proof of Mechanism in Healthy Volunteers for SYNB1020, a Synthetic BioticTM Medicine for the Treatment of Hyperammonemia

Synlogic Receives Orphan Drug Designation for SYNB1618, a Synthetic BioticTM Medicine for the Treatment of Phenylketonuria

Synlogic Strengthens Leadership Team with Appointment of Chief Operating Officer and Chief Human Resources Officer

Synlogic to Webcast Presentation at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

Synlogic Presents New Preclinical Data at International Congress of Inborn Errors of Metabolism

Synlogic to Webcast Presentation at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference

Synlogic Completes Merger with Mirna Therapeutics

Synlogic Receives Fast Track Designation in U.S. for Lead Candidate, SYNB1020

Synlogic™ Doses First Subject in Phase 1 Trial of Novel Class of Synthetic Biotic™ Medicines

Synlogic Meets First Discovery Milestone in Partnership with AbbVie